Shorepath Capital Management LLC Has $3.52 Million Stake in Danaher Corporation $DHR

Shorepath Capital Management LLC trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 46.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,798 shares of the conglomerate’s stock after selling 15,415 shares during the period. Danaher makes up approximately 2.9% of Shorepath Capital Management LLC’s investment portfolio, making the stock its 14th largest position. Shorepath Capital Management LLC’s holdings in Danaher were worth $3,516,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Assetmark Inc. grew its stake in Danaher by 14.0% during the second quarter. Assetmark Inc. now owns 47,464 shares of the conglomerate’s stock worth $9,376,000 after buying an additional 5,843 shares in the last quarter. HBK Sorce Advisory LLC grew its stake in Danaher by 8.6% during the second quarter. HBK Sorce Advisory LLC now owns 3,141 shares of the conglomerate’s stock worth $620,000 after buying an additional 250 shares in the last quarter. Hantz Financial Services Inc. grew its stake in Danaher by 1.1% during the second quarter. Hantz Financial Services Inc. now owns 12,349 shares of the conglomerate’s stock worth $2,439,000 after buying an additional 134 shares in the last quarter. Arkadios Wealth Advisors grew its stake in Danaher by 90.0% during the second quarter. Arkadios Wealth Advisors now owns 8,903 shares of the conglomerate’s stock worth $1,759,000 after buying an additional 4,218 shares in the last quarter. Finally, Lathrop Investment Management Co. grew its stake in Danaher by 7.0% during the second quarter. Lathrop Investment Management Co. now owns 24,584 shares of the conglomerate’s stock worth $4,856,000 after buying an additional 1,605 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 1.3%

DHR opened at $213.99 on Thursday. The company’s 50 day moving average is $203.12 and its 200-day moving average is $199.20. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The company has a market cap of $151.15 billion, a P/E ratio of 44.12, a PEG ratio of 3.32 and a beta of 0.77.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period last year, the company earned $1.71 EPS. The firm’s revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Insider Buying and Selling

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

DHR has been the topic of a number of analyst reports. Barclays increased their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Evercore ISI raised their price target on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, October 25th. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research note on Wednesday, October 8th. Eighteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.